KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Income (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Operating Income data on record, last reported at $23.2 million in Q4 2025.

  • For Q4 2025, Operating Income rose 39.12% year-over-year to $23.2 million; the TTM value through Dec 2025 reached $125.5 million, up 418.63%, while the annual FY2025 figure was $125.5 million, 418.63% up from the prior year.
  • Operating Income reached $23.2 million in Q4 2025 per RIGL's latest filing, down from $28.4 million in the prior quarter.
  • Across five years, Operating Income topped out at $61.1 million in Q2 2025 and bottomed at -$26.3 million in Q1 2022.
  • Average Operating Income over 5 years is $3.1 million, with a median of -$2.0 million recorded in 2023.
  • Peak YoY movement for Operating Income: tumbled 162.89% in 2022, then skyrocketed 13569.57% in 2025.
  • A 5-year view of Operating Income shows it stood at -$21.4 million in 2021, then surged by 109.71% to $2.1 million in 2022, then fell by 5.44% to $2.0 million in 2023, then surged by 747.15% to $16.7 million in 2024, then surged by 39.12% to $23.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were $23.2 million in Q4 2025, $28.4 million in Q3 2025, and $61.1 million in Q2 2025.